Add time:07/12/2019         Source:sciencedirect.com

ObjectivesThe aim of this study was to determine whether the reduction in peripheral revascularization with vorapaxar in patients with peripheral artery disease (PAD) is directionally consistent across indications, including acute limb ischemia, progressively disabling symptoms, or both.

We also recommend Trading Suppliers and Manufacturers of Vorapaxar Sulfate (cas 705260-08-8). Pls Click Website Link as below: cas 705260-08-8 suppliers